A detailed history of Newbridge Financial Services Group, Inc. transactions in Bio N Tech Se stock. As of the latest transaction made, Newbridge Financial Services Group, Inc. holds 99 shares of BNTX stock, worth $11,194. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99
Previous 224 55.8%
Holding current value
$11,194
Previous $18,000 38.89%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$78.36 - $124.66 $9,795 - $15,582
-125 Reduced 55.8%
99 $11,000
Q2 2024

Sep 11, 2024

SELL
$80.36 - $102.87 $22,581 - $28,906
-281 Reduced 55.64%
224 $18,000
Q1 2024

Apr 24, 2024

SELL
$88.96 - $112.35 $31,047 - $39,210
-349 Reduced 40.87%
505 $46,000
Q4 2023

Mar 28, 2024

SELL
$90.91 - $112.75 $24,182 - $29,991
-266 Reduced 23.75%
854 $90,000
Q2 2023

Jul 21, 2023

SELL
$102.58 - $129.66 $5,847 - $7,390
-57 Reduced 4.84%
1,120 $120,000
Q1 2023

Apr 18, 2023

SELL
$122.57 - $153.67 $2,206 - $2,766
-18 Reduced 1.51%
1,177 $146,000
Q4 2022

Jan 17, 2023

SELL
$118.43 - $186.05 $10,658 - $16,744
-90 Reduced 7.0%
1,195 $0
Q3 2022

Oct 13, 2022

SELL
$127.65 - $183.11 $24,508 - $35,157
-192 Reduced 13.0%
1,285 $173,000
Q2 2022

Jul 15, 2022

SELL
$123.25 - $186.24 $6,655 - $10,056
-54 Reduced 3.53%
1,477 $220,000
Q1 2022

Apr 26, 2022

SELL
$126.25 - $231.85 $11,615 - $21,330
-92 Reduced 5.67%
1,531 $261,000
Q3 2021

Oct 27, 2021

SELL
$205.93 - $447.23 $298,186 - $647,589
-1,448 Reduced 47.15%
1,623 $443,000
Q2 2021

Sep 07, 2021

BUY
$113.32 - $241.49 $37,848 - $80,657
334 Added 12.2%
3,071 $688,000
Q1 2021

Sep 07, 2021

SELL
$85.73 - $119.5 $10,973 - $15,296
-128 Reduced 4.47%
2,737 $299,000
Q4 2020

Sep 07, 2021

BUY
$72.71 - $129.54 $208,314 - $371,132
2,865 New
2,865 $234,000

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $27.4B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Newbridge Financial Services Group, Inc. Portfolio

Follow Newbridge Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.